image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 2.34
0 %
$ 13.8 M
Market Cap
-2.96
P/E
1. INTRINSIC VALUE

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time.[ Read More ]

The intrinsic value of one PMD stock under the base case scenario is HIDDEN Compared to the current market price of 2.34 USD, Psychemedics Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PMD

image
FINANCIALS
22.1 M REVENUE
-12.45%
-2.92 M OPERATING INCOME
-169.71%
-4.15 M NET INCOME
-283.21%
-1.48 M OPERATING CASH FLOW
-30.27%
-159 K INVESTING CASH FLOW
23.56%
-1.15 M FINANCING CASH FLOW
40.38%
5.18 M REVENUE
9.45%
-595 K OPERATING INCOME
33.82%
-535 K NET INCOME
35.31%
263 K OPERATING CASH FLOW
119.17%
2 K INVESTING CASH FLOW
-92.59%
-294 K FINANCING CASH FLOW
-119.40%
Balance Sheet Decomposition Psychemedics Corporation
image
Current Assets 6.8 M
Cash & Short-Term Investments 1.96 M
Receivables 3.7 M
Other Current Assets 1.14 M
Non-Current Assets 5.52 M
Long-Term Investments 0
PP&E 4.89 M
Other Non-Current Assets 632 K
Current Liabilities 4.71 M
Accounts Payable 752 K
Short-Term Debt 2.4 M
Other Current Liabilities 1.56 M
Non-Current Liabilities 945 K
Long-Term Debt 945 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Psychemedics Corporation
image
Revenue 22.1 M
Cost Of Revenue 13.7 M
Gross Profit 8.41 M
Operating Expenses 11.3 M
Operating Income -2.92 M
Other Expenses 1.23 M
Net Income -4.15 M
RATIOS
38.07% GROSS MARGIN
38.07%
-13.22% OPERATING MARGIN
-13.22%
-18.80% NET MARGIN
-18.80%
-62.26% ROE
-62.26%
-33.70% ROA
-33.70%
-43.98% ROIC
-43.98%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Psychemedics Corporation
image
Net Income -4.15 M
Depreciation & Amortization 2.67 M
Capital Expenditures -157 K
Stock-Based Compensation 908 K
Change in Working Capital -1.73 M
Others -2.27 M
Free Cash Flow -1.64 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Psychemedics Corporation
image
PMD has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.07 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Psychemedics Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Aug 17, 2023
Sell 59.2 K USD
Doucot Charles M
Executive Vice President
- 12700
4.66 USD
1 year ago
Dec 16, 2022
Bought 495 USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
+ 100
4.95 USD
2 years ago
Apr 20, 2022
Bought 13.1 K USD
Kamin Peter
10 percent owner
+ 1950
6.72 USD
2 years ago
Apr 19, 2022
Bought 76.3 K USD
Kamin Peter
director:
+ 11706
6.52 USD
2 years ago
Apr 20, 2022
Bought 54.4 K USD
Kamin Peter
10 percent owner
+ 8100
6.72 USD
2 years ago
Apr 20, 2022
Bought 25.6 K USD
Kamin Peter
10 percent owner
+ 3808
6.72 USD
2 years ago
Apr 19, 2022
Bought 98.8 K USD
Kamin Peter
10 percent owner
+ 15152
6.52 USD
2 years ago
Apr 20, 2022
Bought 12.1 K USD
Kamin Peter
10 percent owner
+ 1800
6.72 USD
2 years ago
Apr 19, 2022
Bought 4.09 K USD
Kamin Peter
10 percent owner
+ 627
6.52 USD
2 years ago
Apr 07, 2022
Bought 27.2 K USD
Kamin Peter
director:
+ 4000
6.79 USD
2 years ago
Apr 07, 2022
Bought 20 K USD
Kamin Peter
10 percent owner
+ 3000
6.68 USD
2 years ago
Mar 31, 2022
Bought 31.8 K USD
Kamin Peter
10 percent owner
+ 4589
6.92 USD
2 years ago
Mar 31, 2022
Bought 31.8 K USD
Kamin Peter
Director
+ 4589
6.92 USD
2 years ago
Mar 30, 2022
Bought 53.8 K USD
Kamin Peter
Director
+ 7814
6.88 USD
2 years ago
Mar 30, 2022
Bought 53.8 K USD
Kamin Peter
10 percent owner
+ 7814
6.88 USD
2 years ago
Mar 16, 2022
Bought 26 K USD
Kamin Peter
director:
+ 4000
6.51 USD
3 years ago
Dec 11, 2020
Bought 4.95 K USD
WEINERT FRED J
Director
+ 1000
4.95 USD
3 years ago
Dec 08, 2020
Bought 5 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 1000
5 USD
3 years ago
Dec 08, 2020
Bought 5 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 1000
5 USD
4 years ago
Nov 18, 2020
Bought 2.1 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
+ 500
4.2 USD
4 years ago
Nov 13, 2020
Bought 7.84 K USD
WEINERT FRED J
Director
+ 2000
3.92 USD
4 years ago
Nov 13, 2020
Bought 7.98 K USD
ALLEN A CLINTON
Director
+ 2000
3.99 USD
4 years ago
Nov 12, 2020
Bought 3.79 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 1000
3.79 USD
4 years ago
Nov 12, 2020
Bought 3.93 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 1000
3.93 USD
5 years ago
Jun 14, 2019
Bought 9.99 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 1000
9.99 USD
5 years ago
Jun 14, 2019
Bought 9.99 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 1000
9.99 USD
5 years ago
Jun 12, 2019
Sell 27.6 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 2800
9.84 USD
5 years ago
Jun 13, 2019
Sell 25.8 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 2631
9.82 USD
5 years ago
Jun 14, 2019
Sell 37.5 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 3900
9.61 USD
5 years ago
Jun 05, 2019
Bought 4.95 K USD
Doucot Charles M
Vice President Sales & Mktg
+ 500
9.901 USD
5 years ago
Mar 11, 2019
Sell 116 K USD
Lerner Neil
VP - Finance
- 7645
15.11 USD
5 years ago
Mar 12, 2019
Sell 21.3 K USD
Lerner Neil
VP - Finance
- 1412
15.06 USD
6 years ago
Sep 06, 2018
Sell 122 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 6324
19.23 USD
6 years ago
May 21, 2018
Sell 60.7 K USD
Lerner Neil
VP - Finance
- 3013
20.14 USD
6 years ago
May 22, 2018
Sell 37.6 K USD
Lerner Neil
VP - Finance
- 1879
19.99 USD
7 years ago
Nov 14, 2017
Bought 16.9 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 1000
16.88 USD
7 years ago
Sep 01, 2017
Sell 20.8 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 981
21.16 USD
7 years ago
Sep 05, 2017
Sell 89.6 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 4400
20.37 USD
7 years ago
Sep 06, 2017
Sell 43.6 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 2167
20.14 USD
7 years ago
May 10, 2017
Sell 61.3 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 3000
20.43 USD
7 years ago
Mar 09, 2017
Sell 216 K USD
Dyke James V.
Vice President - Sales
- 10513
20.56 USD
7 years ago
Dec 13, 2016
Sell 37.6 K USD
Dyke James V.
Vice President - Sales
- 1630
23.05 USD
7 years ago
Dec 14, 2016
Sell 78.6 K USD
Dyke James V.
Vice President - Sales
- 3461
22.72 USD
7 years ago
Nov 21, 2016
Sell 20.2 K USD
WEINERT FRED J
Director
- 800
25.19 USD
7 years ago
Nov 23, 2016
Sell 17 K USD
WEINERT FRED J
Director
- 701
24.21 USD
7 years ago
Nov 28, 2016
Sell 24.8 K USD
WEINERT FRED J
Director
- 1000
24.77 USD
7 years ago
Nov 29, 2016
Sell 25 K USD
WEINERT FRED J
Director
- 1000
25.05 USD
7 years ago
Dec 06, 2016
Sell 11.6 K USD
WEINERT FRED J
Director
- 500
23.19 USD
7 years ago
Dec 08, 2016
Sell 2.36 K USD
WEINERT FRED J
Director
- 100
23.56 USD
7 years ago
Dec 09, 2016
Sell 11.6 K USD
WEINERT FRED J
Director
- 500
23.22 USD
8 years ago
Nov 18, 2016
Sell 74.2 K USD
Lerner Neil
VP - Finance
- 3000
24.75 USD
8 years ago
Nov 14, 2016
Sell 118 K USD
Dyke James V.
Vice President - Sales
- 5000
23.7 USD
8 years ago
Nov 15, 2016
Sell 117 K USD
Dyke James V.
Vice President - Sales
- 5000
23.42 USD
8 years ago
Mar 02, 2016
Bought 8.98 K USD
CONNICK HARRY F SR
Director
+ 700
12.83 USD
8 years ago
Mar 02, 2016
Bought 8.98 K USD
CONNICK HARRY F SR
Director
+ 700
12.83 USD
8 years ago
Feb 26, 2016
Bought 5.04 K USD
CONNICK HARRY F SR
Director
+ 400
12.61 USD
8 years ago
Feb 26, 2016
Bought 7.59 K USD
CONNICK HARRY F SR
Director
+ 600
12.65 USD
8 years ago
Feb 24, 2016
Bought 3.62 K USD
CONNICK HARRY F SR
Director
+ 300
12.05 USD
8 years ago
Feb 24, 2016
Bought 8.5 K USD
CONNICK HARRY F SR
Director
+ 700
12.15 USD
8 years ago
Feb 22, 2016
Bought 5.04 K USD
CONNICK HARRY F SR
Director
+ 400
12.6 USD
8 years ago
Feb 22, 2016
Bought 7.57 K USD
CONNICK HARRY F SR
Director
+ 600
12.61 USD
8 years ago
Feb 19, 2016
Bought 12 K USD
CONNICK HARRY F SR
Director
+ 1000
11.95 USD
8 years ago
Feb 19, 2016
Bought 12 K USD
CONNICK HARRY F SR
Director
+ 1000
11.95 USD
8 years ago
Feb 16, 2016
Bought 50 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
+ 4507
11.09 USD
9 years ago
Sep 10, 2015
Bought 31 K USD
Lerner Neil
VP - Finance
+ 3000
10.32 USD
9 years ago
Sep 14, 2015
Bought 10 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 1000
9.995 USD
9 years ago
Sep 10, 2015
Bought 10.2 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 1000
10.25 USD
9 years ago
Jun 15, 2015
Sell 23.4 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 1601
14.605 USD
9 years ago
Jun 16, 2015
Sell 18.1 K USD
SCHAFFER MICHAEL I
VP of Laboratory Operations
- 1236
14.65 USD
11 years ago
Nov 27, 2012
Sell 11.8 K USD
Dyke James V.
Vice President - Sales
- 1024
11.55 USD
11 years ago
Nov 27, 2012
Sell 1.16 K USD
Dyke James V.
Vice President - Sales
- 100
11.56 USD
11 years ago
Nov 27, 2012
Sell 2.32 K USD
Dyke James V.
Vice President - Sales
- 200
11.6 USD
11 years ago
Nov 27, 2012
Sell 19.5 K USD
Dyke James V.
Vice President - Sales
- 1676
11.61 USD
12 years ago
Jun 15, 2012
Bought 24.5 K USD
Lerner Neil
VP - Finance
+ 2500
9.8 USD
12 years ago
Jun 15, 2012
Bought 24.5 K USD
Lerner Neil
VP - Finance
+ 2500
9.8 USD
13 years ago
May 25, 2011
Bought 59 K USD
Lerner Neil
VP - Finance
+ 5895
10.01 USD
13 years ago
Mar 17, 2011
Bought 18.2 K USD
Lerner Neil
Vice President and Controller
+ 2000
9.091 USD
15 years ago
Mar 06, 2009
Bought 3.84 K USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 900
4.27 USD
15 years ago
Mar 06, 2009
Bought 426 USD
KUBACKI RAYMOND C JR
Chairman, CEO & President
+ 100
4.26 USD
16 years ago
Jun 12, 2008
Sell 41 K USD
THISTLE WILLIAM R
Sr. VP and Gen. Counsel
- 2410
17 USD
16 years ago
May 09, 2008
Sell 15.3 K USD
THISTLE WILLIAM R
Sr. VP and Gen. Counsel
- 900
17 USD
17 years ago
Mar 08, 2007
Sell 16.8 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 1000
16.82 USD
17 years ago
Mar 08, 2007
Sell 16.8 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 1000
16.81 USD
17 years ago
Mar 08, 2007
Sell 88.2 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 5250
16.8 USD
17 years ago
Mar 08, 2007
Sell 41.9 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 2500
16.75 USD
17 years ago
Mar 06, 2007
Sell 16.9 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 1000
16.93 USD
17 years ago
Mar 06, 2007
Sell 22.8 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 1350
16.91 USD
17 years ago
Mar 07, 2007
Sell 8.45 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 500
16.9 USD
17 years ago
Mar 06, 2007
Sell 8.44 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 500
16.88 USD
17 years ago
Mar 07, 2007
Sell 8.42 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 500
16.85 USD
17 years ago
Mar 05, 2007
Sell 42.2 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 2500
16.9 USD
17 years ago
Mar 05, 2007
Sell 8.44 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 500
16.88 USD
17 years ago
Feb 27, 2007
Sell 33.4 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 2000
16.7 USD
17 years ago
Feb 27, 2007
Sell 11.7 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 700
16.69 USD
17 years ago
Feb 26, 2007
Sell 41.8 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 2500
16.7 USD
17 years ago
Feb 27, 2007
Sell 4.9 K USD
MONSON PETER C
VP, Treas., CFO & Asst. Sec.
- 300
16.32 USD
19 years ago
Apr 01, 2005
Sell 21.4 K USD
KUBACKI RAYMOND C JR
Chairman, CEO and President
- 1600
13.37 USD
19 years ago
Apr 04, 2005
Sell 68.6 K USD
KUBACKI RAYMOND C JR
Chairman, CEO and President
- 5200
13.2 USD
19 years ago
Mar 22, 2005
Sell 110 K USD
KUBACKI RAYMOND C JR
Chairman, CEO and President
- 8025
13.695 USD
19 years ago
Mar 29, 2005
Sell 148 K USD
KUBACKI RAYMOND C JR
Chairman, CEO and President
- 11000
13.5 USD
19 years ago
Mar 29, 2005
Sell 4.06 K USD
KUBACKI RAYMOND C JR
Chairman, CEO and President
- 300
13.52 USD
19 years ago
Mar 29, 2005
Sell 59.5 K USD
KUBACKI RAYMOND C JR
Chairman, CEO and President
- 4400
13.53 USD
19 years ago
Mar 29, 2005
Sell 40.6 K USD
KUBACKI RAYMOND C JR
Chairman, CEO and President
- 3000
13.55 USD
19 years ago
Mar 22, 2005
Sell 110 K USD
KUBACKI RAYMOND C JR
Chairman, CEO and President
- 8025
13.695 USD
19 years ago
Feb 22, 2005
Sell 72.8 K USD
CHRISTOPH RICHARD T
10 percent owner
- 5600
13 USD
19 years ago
Feb 22, 2005
Sell 330 K USD
CHRISTOPH RICHARD T
10 percent owner
- 25419
13 USD
19 years ago
Feb 22, 2005
Sell 129 K USD
CHRISTOPH RICHARD T
10 percent owner
- 9900
13 USD
20 years ago
Jan 07, 2004
Sell 508 K USD
CHRISTOPH RICHARD T
10 percent owner
- 50000
10.15 USD
20 years ago
Jan 07, 2004
Sell 508 K USD
CHRISTOPH RICHARD T
10 percent owner
- 50000
10.15 USD
7. News
Psychemedics Corporation Reports Third Quarter 2024 Financial Results DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024. globenewswire.com - 4 days ago
Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report. globenewswire.com - 1 month ago
Psychemedics Corporation Reports Second Quarter 2024 Financial Results DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024. globenewswire.com - 3 months ago
Psychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common Stock DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”) comprised of independent directors has recommended, and the Board has approved, a plan to cease the registration of the Company's common stock under the federal securities laws following the completion of a proposed reverse stock split and to delist its shares of common stock from trading on the Nasdaq Capital Market. It is expected that this plan would be effectuated in the fall of 2024, assuming the approval of Psychemedics' stockholders at the Company's 2024 Annual Meeting of Stockholders, among other things, as described below. globenewswire.com - 3 months ago
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a vast dataset of hair samples collected and analyzed in 2023. globenewswire.com - 4 months ago
Psychemedics Corporation Reports First Quarter 2024 Financial Results DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024. globenewswire.com - 6 months ago
Psychemedics Corporation Reports 2023 Financial Results DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. globenewswire.com - 7 months ago
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics' commitment to excellence and innovation in the field of employee health testing. globenewswire.com - 7 months ago
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing. globenewswire.com - 10 months ago
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. globenewswire.com - 11 months ago
Psychemedics Corporation Reports Third Quarter 2023 Financial Results ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. globenewswire.com - 1 year ago
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen Psychemedics debuts a 5-panel drug test replacing marijuana with fentanyl, the first hair drug test exclusively targeting the most dire workplace threats. globenewswire.com - 1 year ago
8. Profile Summary

Psychemedics Corporation PMD

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 13.8 M
Dividend Yield 0.00%
Description Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
Contact 289 Great Road, Acton, MA, 01720 https://www.psychemedics.com
IPO Date Jan. 22, 1987
Employees 116
Officers Ms. Shannon Shoemaker Vice President & Chief Revenue Officer Mr. Brian Hullinger President, Chief Executive Officer & Director Ms. Daniella Mehalik Vice President of Finance Mr. Michael Weisenhoff Principal Financial & Accounting Manager Mr. Patrick J. Kinney Jr. Secretary Dr. Werner A. Baumgartner Ph.D. Founder Ms. Annette Baumgartner Founder